Thromboembolism and the Oxford–AstraZeneca COVID-19 vaccine: side-effect or coincidence?
Open Access
- 30 March 2021
- journal article
- letter
- Published by Elsevier BV in The Lancet
- Vol. 397 (10283), 1441-1443
- https://doi.org/10.1016/s0140-6736(21)00762-5
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clotsPublished by BMJ ,2021
- Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trialsThe Lancet, 2021
- Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trialThe Lancet, 2020
- The Danish health care system and epidemiological research: from health care contacts to database recordsClinical Epidemiology, 2019
- Venous Thromboembolism in Denmark: Seasonality in Occurrence and MortalityTH Open, 2019
- Risk of bleeding and arterial cardiovascular events in patients with splanchnic vein thrombosis in Denmark: a population-based cohort studyThe Lancet Haematology, 2018
- The Danish National Patient Registry: a review of content, data quality, and research potentialClinical Epidemiology, 2015
- Secular Trends in Occurrence of Acute Venous Thromboembolism: The Worcester VTE Study (1985-2009)The American Journal of Medicine, 2014
- Incidence of and Mortality from Venous Thromboembolism in a Real-world Population: The Q-VTE Study CohortThe American Journal of Medicine, 2013
- Incidence and mortality of venous thrombosis: a population‐based studyJournal of Thrombosis and Haemostasis, 2007